Report Overview

The UK Phenylketonuria Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Phenylketonuria (PKU) is a rare inherited condition that causes a build-up of Phenylalanine. Phenylalanine (Phe) is one of 20 amino acids that make up the building blocks of protein. Proteins are made up of building blocks called amino acids. In PKU, the body cannot break down the amino acid phenylalanine it builds up in the blood and tissues. This build-up prevents the brain from developing properly. Progressive intellectual disability results if PKU is not treated from early infancy. With treatment, children with PKU can grow and develop normally. People with PKU need to follow a diet that limits foods with phenylalanine. The diet should be followed carefully and be started as soon after birth as possible. Food mainly suggested are Milk and cheese, Eggs, Nuts, Soybeans, Beans, Chicken, beef, or pork, Fish, Peas, Beer.

With an early diagnosis and the correct treatment, most children with PKU are able to live healthy lives. The prevalence of PKU is around 1:10,000 babies born in the UK. PKU affects approximately 70 babies each year. Males and females are affected equally by PKU in the UK. Parents of a child with PKU have about one in four chances of having another child with the debilitating condition.



Market Growth Drivers

Frequent research for the development of novel drugs for the treatment of PKU is expected to drive the growth of the PKU treatment market during the forecast period. Furthermore, increasing acquisitions and collaborations between key players are also expected to create a lucrative environment for the growth of the PKU treatment market during the forecast period.

In recent years, small and large pharmaceutical and nutraceutical companies have become increasingly dependent on contract research organizations (CROs) and other clinical services to provide research services to their R&D operation. Also, phenylketonuria treatment-based products and rising demand for essential and nonessential amino acids in the form of protein ingredients as well as finished products are expected to drive market growth during the forecast period.

Market Restraints

However, rising treatment costs and a lack of awareness among patients and physicians about phenylketonuria are among the major factors acting as restraints and will continue to pose a challenge to the PKU treatment market during the forecast period.